The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Age 18-75 years old (including boundary values), regardless of gender.
Confirmed as late stage MPM patients who have failed immunotherapy.
The patient or their legal representative can understand and sign the informed consent form.
At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods.
Physicians participating in the study believe that patients may not be able to provide continuous follow-up information.
Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases).
Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)